Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
Provided By GlobeNewswire
Last update: Apr 1, 2025
The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction
Read more at globenewswire.com1
-0.05 (-4.76%)
Find more stocks in the Stock Screener
CMND Latest News and Analysis
2 days ago - ChartmillWhich stocks have an unusual volume on Monday?Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.
